Exhibit 99.1 Personalis Reports First Quarter 2024 Financial Results Raises full year revenue guidance due to greater pharma testing demand FREMONT, Calif. – May 8, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights. Recent Business Highlights First Quarter Results 1 • The analytical validation for the company's NeXT Personal MRD test was pub ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Daniel Sammarco - TD Cowen Operator Greetings, and welcome to the Personalis ...

Revenue Growth - Total revenue increased by 13%, or $8.4 million, in 2023 compared to 2022, driven by higher revenue from enterprise sales and pharma tests [348]. - Revenue from enterprise sales was $31.7 million in 2023, up 19% from $26.6 million in 2022; revenue from pharma tests was $31.9 million, an 8% increase from $29.6 million [348]. - Total revenue for 2023 was $73,481,000, representing a 13% increase from $65,047,000 in 2022 [364]. - Revenue from pharma tests and services increased by 8%, or $2.4 million, driven by new customer growth [365]. - Enterprise sales revenue rose by 19%, or $5.1 million, with a 55% increase in samples processed for Natera [366]. - Population sequencing revenue increased by 11%, despite a nearly 50% reduction in selling prices [368]. - Revenue from Natera, Inc. accounted for 43% of total revenue in 2023, up from 41% in 2022, indicating a strong reliance on this customer [440]. - Revenue from international customers represented 10% of total revenue in 2023, up from 9% in 2022 and 8% in 2021 [480]. - Revenue from Pharma tests and services was $31,904,000 in 2023, up from $29,552,000 in 2022, reflecting a growth of 7.9% [480]. - Enterprise sales revenue increased significantly to $31,729,000 in 2023, compared to $26,641,000 in 2022, marking a growth of 19.5% [480]. Financial Performance - The company incurred a net loss of $56.3 million in operating activities for the year ended December 31, 2023, an improvement from a loss of $70.2 million in 2022 [389]. - Net loss for 2023 was $108,296,000, a slight improvement from a net loss of $113,315,000 in 2022 [416]. - Cash flows used in operating activities decreased to $56.258 million in 2023 from $70.233 million in 2022, indicating improved cash management [425]. - The company recognized $8.1 million in restructuring charges due to workforce reductions and closure of operations in China [378]. - The accumulated deficit grew to $468,706,000 in 2023 from $360,410,000 in 2022, an increase of 30% [414]. - Total liabilities increased to $95,658,000 in 2023 from $74,561,000 in 2022, marking a rise of 28% [414]. - The company has incurred net losses since inception and anticipates that current cash and cash equivalents are sufficient to fund near-term capital and operating needs for at least the next 12 months [385]. Cost Management - Cash burn was reduced by nearly 50% through workforce reduction, resulting in estimated annual cost savings of $35 million [349]. - Selling, general, and administrative expenses have decreased significantly and are expected to remain at lower levels over the next couple of years [356]. - Research and development expenses are expected to decrease due to workforce reductions and the closure of operations in China [354]. - Selling, general and administrative expenses decreased by 22%, or $14.2 million, primarily due to workforce reductions [374]. - Research and development expenses remained flat at $64,776,000, with increases in clinical evidence generation costs offset by workforce reductions [372]. Cash and Investments - As of December 31, 2023, cash and cash equivalents totaled $114,179,000, down from $167,658,000 in 2022 [362]. - The company plans to fund its material cash requirements with existing cash and cash equivalents, which amounted to $114.2 million as of December 31, 2023 [392]. - The company reported a decrease in cash provided by investing activities of $39.4 million in 2023 compared to 2022, primarily due to lower net proceeds from short-term investment maturities [390]. - The total cash, cash equivalents, and restricted cash at the end of the period was $58.774 million, down from $90.918 million at the end of 2022 [425]. - The company generated $13.099 million in net cash from investing activities in 2023, compared to $52.537 million in 2022 [425]. Strategic Partnerships and Developments - Medicare coverage was received for NeXT Dx, and a partnership with Tempus was established to commercialize NeXT Personal Dx in clinical settings [349]. - The company is focusing on three key indications: breast cancer, lung cancer, and immunotherapy monitoring, collaborating with leading cancer centers and academic institutions [346]. - The company has invested significantly in its NeXT platform, introducing new products and capabilities to support growth [350]. - The Company entered into a Commercialization and Reference Laboratory Agreement with Tempus, which includes potential fees of up to $12 million for development activities [508]. - The Company received $6 million in Market Development Fees from Tempus upon achieving the first clinical validation milestone [514]. Workforce and Operations - The Company initiated a reduction in workforce affecting nearly 100 employees in January 2023, incurring $3.1 million in one-time termination benefits [519]. - A second workforce reduction affecting approximately 60 employees was initiated in December 2023, with expected costs of $4.0 million in termination benefits [520]. - The Company terminated its operations in China during the first half of 2023, incurring $0.9 million in expenses related to closure activities [522]. - The company has terminated its operations in China and dissolved its subsidiary, Personalis (Shanghai) Ltd., in February 2024 [430]. Legal Matters - The Company filed a patent infringement complaint against Foresight Diagnostics Inc. on August 2, 2022, asserting four patents related to personalized genetic testing and analysis [540]. - An amended complaint was filed on August 17, 2022, adding a fifth patent, with the Company seeking injunctive relief, damages, and costs [540]. - The District Court granted Foresight's motion to stay the patent infringement action on January 24, 2023, pending the inter partes review proceedings [541]. - The USPTO granted inter partes reviews for the '394 and '033 Patents on June 13, 2023, and for the '611 and '783 Patents on August 8, 2023 [541]. - A second patent infringement complaint was filed by the Company on June 26, 2023, asserting two additional patents related to methods for using mosaicism in nucleic acids [542].

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Participating on Tuesday, February 13, 2024 at The Cliff Lodge in Snowbird, UT 44th Annual Cowen Healthcare Conference Presenting on Wednesday, March 6, 2024 at 12:50 p.m. Eastern Time at the Boston Marriott Copley Place in Bost ...

FREMONT, Calif. & SAN DIEGO--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform. “We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health’s blood-based ep ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 29,000 shares of its common stock to eight new employees under Personalis’ 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, o ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries. Matching patients to their optimal cancer therapy requires a testing platform that can accurately report a broader range of clinically actionable genomic alt ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter Revenue and Cash Balance Preliminary total company revenue is estimated to be $19.7 million in the fourth quarter of 2023, an increase of 18% compared with $16.7 million in the fourth quarter of 2022 Preliminary revenue from pharma tests, enterprise ...

Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - Chief Medical Officer and EVP, Research and Development Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Mark Massaro - VTIG Swayampakula Ramakanth - H.C. Wainwright Operator Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call. All participants ...